How much is the latest price of Sparsenton?
Sparsentan is an innovative drug that has not yet been launched in China. For patients who are in urgent need of its treatment, overseas formal channels have become their hope for obtaining the drug. In the Laotian market, Lucius's version of Sparsentan has received widespread attention for its unique curative effect and quality. Currently, the latest price of its 400mg*30 tablets is stable at around 8 thousand yuan, providing a relatively reasonable choice for many patients.
However, purchasing drugs overseas is not easy, and patients must be cautious when choosing purchasing channels. Ensuring that the chosen channel is legal and legal is the key to avoiding purchasing counterfeit and shoddy products. At the same time, drug prices are affected by many factors such as market demand and supply chain conditions. Therefore, patients should conduct sufficient market research and consult professional medical professionals before purchasing to ensure the safety and effectiveness of the medication.
Sparsentan, with its unique dual antagonist mechanism, has shown significant advantages in the treatment of kidney diseases. It works by simultaneously inhibiting endothelinA type (ETA) receptors and angiotensinII Type 1 (AT1) receptor effectively protects kidney function, reduces proteinuria, and reduces the rate of decline in glomerular filtration rate, thereby delaying the progression of the disease.
Sparsentan is indicated primarily to treat adult IgA nephropathy (immunoglobulinA nephropathy) who are at risk for rapid disease progression. Multiple clinical trials have fully proven its significant efficacy and safety in the treatment of IgA nephropathy, bringing good news to many patients.
However, any medication has its potential side effects. During the use of sparsentan, symptoms such as hypotension, peripheral edema, and dizziness may occur. Therefore, when using sparsentan, patients must strictly follow the doctor's instructions, use the medication rationally, and conduct regular follow-up and examinations to ensure the safety and effectiveness of the medication.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)